Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. Its products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the tropomyosin receptor kinase family tyrosine kinase receptors, ROS1, and anaplastic lymphoma kinase proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, an orally bioavailable and vascular endothelial growth factor receptor, and small molecule tyrosine kinase inhibitor of RET-driven solid tumors; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. The company was founded in 2011 and is headquartered in San Diego, California.
http://www.priceseries.com/trade/RXDX-Ignyta-Inc-stock-gains-40-percent-a-Trade-Record-by-priceSeries-2017060720170629.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments